Login to Your Account



Impact on Biosimilars?

Affymax Crashes on Omontys Recall, Hypersensitivity Data

By Jennifer Boggs
Managing Editor

Tuesday, February 26, 2013
Though decried as an overreaction by analysts at the time, Affymax Inc.'s intraday share drop earlier this month on reports of mild allergic reactions in a pilot study of erythropoiesis-stimulating agent (ESA) Omontys (peginesatide) turned out to be an omen of bad news to come.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription